Contact details for ADR brokers & institutional investors:

U.S. Tel: +1 212 552 8926
Hong Kong Tel: +852 2800 1857
e-mail: drx_depo@jpmorgan.com

Computershare contacts for ADR registered holders of Fresenius: 

Computershare Shareowner Services
Phone (US & Canada – toll free): +1-866-723-8257
Phone (International): +1-781-575-2833
 

For regular correspondence:

Computershare Shareowner Services
P.O. Box 43304 Providence, RI 0290-3304, USA
Email: web.queries@computershare.com
Website: www.computershare.com/investor or www.computershare.com/us/contact-us

For delivery of stock certificates & overnight mail:

Computershare Trust Company, N.A 
150 Royall Street
Canton, MA 02021

Fresenius’ ADR program is administered by J.P. Morgan Chase Bank N.A. As the depositary bank, J.P. Morgan Chase Bank N.A performs the following roles for registered ADR holders as further detailed in the Deposit Agreement:

• Records and maintains the register of ADR holders,
• Is the stock transfer agent,
• Distributes dividends in U.S. dollars,
• Facilitates the voting process and the exercise of the voting rights of ADR holders at any Company General Meeting if permitted by the Company and the Depositary Agreement,
• Issues and cancels Fresenius American Depositary Receipts (ADRs),
• Can distribute Company circulars and General Meetings (including Annual General Meeting) documentation, if applicable.

For those holders who are not registered because their ADRs are held through a ‘Street name’ (nominee account), your nominee will from time to time receive Company documents from J.P. Morgan Chase Bank N.A to distribute to ADR holders. You need to make arrangements with your nominee if you wish to receive such documents and to be able to exercise your vote through the depositary bank at General Meetings (if applicable).

For us, quality excellence means a strong commitment to product and service quality and safety, driven by continuous improvement and effective processes. We want to provide people with access to healthcare innovations and thereby support patient care.

Fresenius provides healthcare services, manufactures pharmaceuticals, and develops medical technology products and solutions. As a result, quality requirements vary across our businesses. Our quality management systems are specifically designed to address these diverse needs, meeting both internal standards and external requirements. We ensure this through robust processes and comprehensive training programs across all areas of our business. To track our performance, we use clearly defined quality indicators and targets. These are not only embedded in our daily work but also tied to the variable compensation of our Management Board.

Innovation is key to meeting the needs of our patients – today and in the future. For us, it is a driving force behind improving treatment options, streamlining workflows, and delivering high-quality healthcare solutions. Our integrated approach spans the entire value chain and focuses, among other things, on initiatives that support the advancement of therapies, informed decision-making, and efficient processes through research, digital health solutions, and Artificial Intelligence.

 ➔ Read more in our Sustainability Statement.

We are committed to respecting internationally recognized human rights. This commitment is embedded in our business practices and across our value chain.

Patients, doctors, nursing and administrative staff rely on our products, concepts, and solutions. Around 180,000 employees place their trust in Fresenius as an employer. Our responsibility also extends to people worldwide who work for our suppliers and business partners in our value chain.

Our Human Rights Program is guided by internationally recognized standards and frameworks, including the Universal Declaration of Human Rights, the Core Labor Standards of the International Labour Organization, the UN Guiding Principles on Business and Human Rights, and the OECD Due Diligence Guidance for Responsible Business Conduct. A central element is our risk-based human rights due diligence. It helps us identify and assess human rights risks and implement appropriate preventive and remedial measures.

➔ Read more on our Human Rights page.

We are committed to high ethical business standards. This commitment is embedded in our values, standards, and governance structures.

Integrity, accountability, and reliability are important foundations of our corporate culture. We hold our business partners and suppliers to the same high standards. We continuously work to prevent misconduct, identify potential violations, and respond appropriately when they occur. 

Our understanding of integrity goes beyond legal requirements. For us, doing the right thing means acting not only in compliance with the law, but also in accordance with applicable industry codes, internal policies, and our values, the Fresenius Principles. Internal and external control mechanisms support us in meeting regulatory requirements and maintaining the trust of our stakeholders.

➔ Read more on our Compliance page. 

Decarbonization at Fresenius means reducing greenhouse gas emissions in our own operations and along our value chain.

Decarbonization at Fresenius means reducing greenhouse gas emissions in our own operations and along our value chain.

Fresenius manufactures medical products and operates healthcare facilities, which inevitably results in energy consumption and associated greenhouse gas emissions. In production, for example, the machines and containers have to be sterilized, and in our hospitals a wide variety of technical systems are in constant operation. This presents us with specific challenges: For us, patient safety always comes first. At the same time, we aim to reduce energy demand as far as possible – without compromising safe care, hygiene, or the reliable manufacturing of our products.

We want to live up to our responsibilities and reduce our greenhouse gas emissions step by step. By 2030, we aim to reduce our Scope 1 and Scope 2 emissions by 50% compared to our 2020 base year. 

Scope 1 and Scope 2 target pathway to 2030

The decarbonization of our value chain is an important part of our long-term journey toward net zero emissions. Scope 3 emissions arise indirectly across our upstream and downstream value chain, for example through purchased raw materials or the treatment of sold products at the end of their life cycle. As the majority of our emissions occur along the value chain, we work with our suppliers to help reduce these emissions.

Climate change is also a health issue. Rising temperatures, more frequent heatwaves and changing weather patterns directly affect people's health, particularly vulnerable groups such as the elderly, chronically ill, and children. Heat stress can lead to circulatory problems, dehydration and an increased risk of death. At the same time, changing climatic conditions can contribute to the spread of infectious diseases and enable their vectors to spread into new regions. . For us as a healthcare company, the impacts of climate change on human health and healthcare delivery are therefore particularly relevant. We see reducing greenhouse gas emissions and ensuring reliable healthcare delivery as closely connected.

Further information on our 2030 climate targets and their implementation can be found in our Sustainability Statement:
➔ Read more in our Sustainability Statement.

Water at Fresenius means using water responsibly and preserving water quality, with a particular focus on reducing water withdrawal in water-stressed areas.

Water is one of our most valuable resources. As a healthcare company, we are dependent on water: We need drinking water of the highest quality to ensure safe patient care. It is crucial for hygiene and well-being. We also use water in the production of our pharmaceutical products – as process water as well as product component. The quality requirements for this water are even higher than those for drinking water. 

We aim to minimize the impacts of our business activities on water resources and the receiving systems into which we discharge our wastewater, and to manage water and wastewater responsibly. We place particular focus on sites in water-stressed areas, where reducing water withdrawal is especially important.

➔ Read more in our Sustainability Statement.

Circularity & Waste at Fresenius means using resources more efficiently by embedding circular principles into our products, processes, waste management and value chains.

We are committed to conserving natural resources wherever possible. As a healthcare company, we must always strike a balance between resource efficiency, hygiene requirements, patient safety and product quality.

Disposable items are often used in clinics for hygienic reasons. Our options for saving resources are limited here. There are also strict regulations for pharmaceutical packaging. Our most important levers for conserving resources are therefore developing durable and resource-saving products, reusing resources wherever possible, and disposing of waste safely and systematically.
 

➔ Read more in our Sustainability Statement.

Patient centricity at Fresenius means prioritizing patient needs and experiences as well as treatment outcomes, and aligning care delivered through medical products and services in inpatient and outpatient settings accordingly.

Every year, millions of people entrust us with their most precious asset: their health. Through our medical expertise, products, and services, we help enable and support medical treatments, contributing to high-quality care, positive treatment outcomes, and a positive patient experience. By providing high-quality care, we aim to contribute to positive treatment outcomes and a positive patient experience. 

Digital technologies can support more personalized and efficient care, both in our hospitals and in the design and use of our products. These include digital processes as well as data-driven and AI-enabled solutions. In specific use cases, they can, for example, support decision-making and care coordination, in line with ethical standards, regulatory and data protection requirements, and the principle of transparency.

Quirónsalud uses the Net Promoter Score (NPS) to measure patient experience in its hospitals and strives to achieve a high score in this metric. The NPS reflects the likelihood of patients recommending the hospital after a hospital contact. 

➔ Read more in our Sustainability Statement.

We strive to provide affordable, high-quality products and services that are accessible to more patients and contribute to enhancing the efficiency of healthcare systems.

Our range of products and services includes the services of a broad network of clinics as well as high-quality pharmaceuticals and medical devices. We also use digitalization opportunities and develop new forms of therapy. In this way, we aim to support access to healthcare for as many people as possible through our products and services.

We contribute to improving access to healthcare by prioritizing patient well-being and supporting employees.

Our growing portfolio includes pharmaceuticals – generics and biosimilars – that offer cost-effective alternatives to originator drugs, and our MedTech and Nutrition products that establish a solid foundation for patient care and recovery.  

Ensuring that our products are available is an important part of patient care. We continuously invest in our global manufacturing network to maintain a reliable and resilient supply of life-saving therapies. By strengthening our supply infrastructure, we help to prevent disruptions and enhance healthcare delivery worldwide.

➔ Read more in our Sustainability Statement.

Employee Engagement & Development means strengthening our purpose-driven performance culture to attract, develop, and retain a motivated workforce. Through their skills and commitment, our employees contribute to healthcare delivery every day.

Committed to Life – our nearly 180,000 employees put this promise into practice every day: whether in direct contact with patients, relatives, and business partners or behind the scenes in administration and production.

As an employer, it is our responsibility to support safe working conditions and foster an environment that enables development and dialogue. We seek direct exchange with our employees. Their diverse experiences and perspectives provide valuable input for the continued development of our working environment. We aim to support employees throughout the different stages of their careers and create opportunities for their professional development and engagement.

 
➔ Read more in our Sustainability Statement.

The Fresenius SE & Co. KGaA Commercial Paper Program enables Fresenius to issue short-term notes of up to €1.5 bn on the money market. The issuances are made through the European Commercial Paper Program (ECP).